Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Overweight at Cantor Fitzgerald
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was upgraded by Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued on Wednesday,Briefing.com Automated Import reports. A number of other research firms have also issued reports on ACRS. StockNews.com raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” […]
More Stories
Fallout Nuka Girl: Release Date, Pricing and More
Have you ever explored the world of the Fallout video gaming series? If yes, you must have probably seen the...
US to Host New Israel–Lebanon Peace Talks
By Ryan Morgan The United States will again host a set of talks between Israeli and Lebanese delegations on May...
US Fighter Jet Disables 2 Iranian Tankers in Blockade Enforcement Action: CENTCOM
By Ryan Morgan A U.S. fighter jet fired on a pair of crude oil tankers as they attempted to bypass...
OpenAI Cofounder Greg Brockman Defends Company’s For-Profit Pivot—and His Own $30 Billion Payday
By Beige Luciano-Adams In the second week of a high-profile jury trial that could have a profound impact on the...
Trump Put Tehran on the Clock
By Mehek Cooke President Donald Trump’s usual naysayers and the foreign policy class are already trying to sell his pause...
US Economy Adds 115,000 Jobs in April, Beating Market Estimates
By Andrew Moran The U.S. labor market could be showing signs of heating up after the economy topped economists’ expectations....